The EMA has published guidance on registry-based studies as a tool to generate RWE

Published date22 October 2020
Subject MatterEU,Clinical Trials,Comment Period,Pharmaceutical Industry,European Medicines Agency (EMA),Marketing Authorization Application,Real World Evidence
AuthorElisabethann Wright
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT